Newsletter | June 13, 2026

06.13.26 -- Life Science Leader Newsletter - Best Of May

MAY'S BEST FEATURED EDITORIAL

Why Europe's Scientific Edge Still Struggles To Attract Global Capital

By Robert Schickel, Ph.D.

European biotech needs specialized capital and stronger continuity across funding stages to get to the next level, writes NUAgo Therapeutics CEO Robert Schickel, Ph.D.

MAY'S BEST INDUSTRY INSIGHTS

Improving Rare Disease Recruitment With Data And AI

Finding patients for rare disease clinical trials can be an uphill battle; fortunately, there are ways sponsors can address the most common stumbling blocks in the recruitment process.

Ophthalmology Patient Engagement And Retention: Point-Of-Need Execution

Dropout in retinal trials is often a logistical failure. Reducing travel burden and bringing specialized care to the patient can slash attrition rates and secure critical trial timelines.

Where CNS Trials Stand In 2026: Breakthroughs Shaping The Path Forward

Explore how AI, digital tools, and site‑centered design can reduce burden, strengthen data quality, and support more reliable trial execution.

Connect With Life Science Leader: